Formulation And Evaluation Of Lipid Nanoparticulate Drug Delivery System Of Aprepitant For The Treatment Of Cinv

Abstract

The present study was to formulate and evaluate the Aprepitant USP is a substance P/neurokinin 1 (NK1) receptor antagonist as nanoparticulate lipid carriers (AP-NLC) drug delivery systems and comparing with the marketed product. The formulations of AP-NLC were prepared by the homogenization followed by ultrasonication method using the solid lipid as Glyceryl behenate, the liquid lipid Caprylocaproyl polyoxyglycerides and polysorbate 80 as hydrophilic surfactant. Based on the trial experiments, the composition of optimized formulation was AP-NLC blend consist of 125 mg of Aprepitant, 210 mg Glyceryl behenate, 90mg Caprylocaproyl polyoxyglycerides, 36 mg polysorbate 80 and 20 mg soya lecithin. By liquisolid technique mesoporous silica gel taken was 160.4 mg was mixed with above AP-NLC blend to form from the optimized AP-NLC12 capsules. The AP NLC12 was found to be with mean particle size of mean average of 200.6 nm with maximum intensity of 541.0 nm particles, The dissolution data demonstrates that the drug release was increased by 5-12 % increase in drug release in initial time points upto 3hrs as compared to the marketed product and the release is sustained up to 30 hrs as compared to the 10 hrs for the marketed product. The drug release kinetics of AP NLC 12 was by Korsmeyer-Peppas model confirms the drug release from a polymeric system and release mechanisms was diffusion followed by erosion.This research is an attempt was made to design Aprepitant USP nanoparticulate lipid carrier drug delivery systems for sustained drug release in treatment chemotherapy induced nausea and vomiting (CINV).